CEO SUMMARY: Since the launch of a laboratory test utilization program in 2011 at the Cleveland Clinic, more than 35,000 duplicate or inappropriate test orders have been stopped. The test utilization team introduced five initiatives that are not designed to cut spending but to introduce evidence-based and consensus-driven methods to lab-test ordering. Another benefit is that needless blood draws are being eliminated, thus improving patient care and satisfaction.
Tag: esoteric lab test
CEO SUMMARY: It was record attendance at the major pathology congress which took place in Hangzhou, China, last month. Because of the ongoing growth of China’s economy, the demand for healthcare—and for high-quality clinical lab and pathology testing—is rising at an accelerated pace. During his visit to the pathology congress and Chinese hospital labs, your
CEO SUMMARY: News that UnitedHealth Group, Inc. added Esoterix, Inc. to its national laboratory services contract is a big story. UnitedHealth’s decision to expand the laboratory panel demonstrates that factors other than lowest price played an important role. The move to supplement its two national labs with a third laboratory option indicates that UnitedHealth’s existing
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab directors at local hospital laboratories. These tests come bundled in high-priced panels and often
CEO SUMMARY: Since the beginning of 2002, several important events changed the competitive status quo among the nation’s leading providers of hospital send-out testing. As part of its ongoing assessment of this market segment, THE DARK REPORT provides strategic management insights from executives at ARUP Laboratories and Mayo Medical Laboratories.
IN THE HOSPITAL SEND-OUT marketplace, a
IT WAS A DISAPPOINTING TRIP to the public equity markets for Dynacare, Inc. last month. The lab company raised only $50 million in its initial public offering (IPO).
Dynacare had hoped to harvest as much as $89 million from this IPO. Plans were to sell seven million shares at about $13 per share. But after Dynacare’s